

Diagnosis of small intestinal bacterial overgrowth in the clinical practice

M. GABRIELLI¹, G. D'ANGELO, T. DI RIENZO, E. SCARPELLINI, V. OJETTI

Department of Internal Medicine, ¹Department of Emergency; School of Medicine, Catholic University of the Sacred Heart, Gemelli Hospital, Rome, Italy

Abstract. – **BACKGROUND:** Gut microbiota plays several beneficial effects on the human host. Its qualitative and/or quantitative unbalance may facilitate the occurrence of small intestinal bacterial overgrowth (SIBO).

AIM: To review the available data in order to propose a practical approach to SIBO diagnosis in the clinical setting.

MATERIALS AND METHODS: Full papers from 1990 to present available on the Pubmed database concerning the topic of SIBO diagnosis were critically reviewed.

RESULTS: SIBO is common in the presence of one or more predisposing conditions. The clinical picture of SIBO patients is extremely variable, depending of underlying disorders, and both patients and microbiota characteristics. SIBO could be asymptomatic, or leading to aspecific gastrointestinal IBS-like symptoms. In worst cases it may configure a real malabsorption syndrome. Culture of intestinal aspirates remains at present the gold standard for SIBO diagnosis. However a lot of limitations including high costs and invasivity prevent from using this test in the clinical practice. Hydrogen lactulose and especially glucose breath tests are at present the most utilized to reach SIBO diagnosis in the clinical setting, due to their low costs, non invasivity, sufficient accuracy and reproducibility.

CONCLUSIONS: SIBO should be suspected in the presence of IBS-like symptoms and/or malabsorption syndrome occurring in the presence of disorders predisposing to SIBO development. The most common diagnostic tool is represented at present by hydrogen breath tests.

Key words:

Small intestinal bacterial overgrowth, Gut microbiota, Diagnosis, Hydrogen breath test, Glucose, Lactulose.

Introduction

Adult humans live in symbiosis with several bacteria species exceeding the number of host somatic cells by at least one order of magnitude¹.

Human intestinal microbiota create a complex polymicrobial ecology composed of viruses, parasites, yeast and, above all, bacteria. Specifically the duodenum and proximal jejunum normally contain small numbers of bacteria (lactobacilli and enterococci, gram-positive aerobes or facultative anaerobes, coliforms may be transiently present). The bacterial concentration varies along the gastrointestinal tract increasing from 10³ colony-forming units (CFU)/ml in the upper intestinal tract to 10¹⁴ CFU/ml in the colon².

The intestinal microbiota was found to play different beneficial effects on the host: protection against pathogenic microorganisms, stimulation of the human immune system, a trophic function on the intestinal mucosa thus participating to the integrity of the gut barrier, production of various nutrients and vitamins. In addition, a favourable effect of gut microbiota on the intestinal motor function has been suggested by recent studies³.

Any unbalance (qualitative and/or quantitative) of this important complex microbiological could have different consequences both locally and systemically, including the occurrence of small intestinal bacterial overgrowth.

There are several mechanisms that may limit overgrowth of intestinal bacterial populations. Among these: anatomic and functional factors (gastric acidity, the continence of ileo-cecal, the bile and pancreatic secretions antibacterial bile secretion and pancreatic), mechanical factors (intestinal peristaltic activity) and factors that inhibit the adhesion of bacteria to the epithelium (production of secretory IgA, the integrity of the mucus layer, epithelial desquamation). It is clear that all the anatomical and/or functional mechanisms able to impair these delicate and complex protection system can determine an abnormal growth of bacteria in the intestinal segments proximal⁴⁻⁶.

Small intestinal bacterial overgrowth (SIBO) is a condition characterized by abnormally high

bacterial population level in the small intestine, exceeding 10^6 organisms/ml^{6,7}.

The aim of the present review is to analyze the available literature data in order to propose a practical approach to SIBO diagnosis in the clinical setting.

Predisposing conditions

The real prevalence of SIBO is unknown at present. In fact it is generally under-diagnosed, because its unspecific symptoms are often attributed to underlying disease predisposing to SIBO⁶. In fact SIBO is extremely common in the presence of one or more of the predisposing conditions. In addition its recurrence after successful antibiotic treatment is high if the underlying disease is not removed/removable⁸.

The prevalence of SIBO rises with age (about 50% in persons > 75 years old)⁹. In fact ancient age is associated to a progressive disruption of more than one of defense mechanisms: decrease of both gastric acid production and intestinal motility are common findings in older people. Diseases associated to achlorhydria such as gastric atrophy or chronic administration of proton pump inhibitors may cause bacterial overgrowth in the stomach and duodenum¹⁰.

SIBO complicates 30%-40% of patients with chronic pancreatitis¹¹. Multiple factors can be involved, as the absence of the antibacterial effects of proteolytic enzymes due to the exocrine pancreatic insufficiency, the motility disorders and drug or alcohol consumption. An increased prevalence of SIBO (56%) has been found in patients with cystic fibrosis also¹².

Syndromes associated to an immune system dysfunction (such as AIDS, IgA deficiency, common variable immunodeficiency) bring to an increased susceptibility to any infection, including SIBO^{13,14}.

Functional dyspepsia and SIBO share the motility disorder as one of the main etiologic factors: studies showed a high prevalence of SIBO in patients with functional dyspepsia, in particular in patients in treatment with proton pump inhibitors¹⁵. SIBO has been also detected in up to 60% of patients with gastroparesis¹⁶.

Thyroid activity may influence gut motility through neurological and muscular mechanisms¹⁷. Several studies showed hypothyroidism to be associated with a slower oro-cecal transit time both in animal and human subjects^{18,19}.

SIBO is associated with all the anatomical disorders characterized by intestinal obstruction and/or stagnation, as adhesion, strictures, tumors.

Tursi et al²⁰ found SIBO in 59% of patients with diverticulitis. This association could be based on a slow oro-cecal transit with the resulting stasis of feces in the colon probably due to slower large bowel transit with stasis of feces in the colon.

Celiac disease is variably complicated by SIBO (9%-55%)²¹⁻²³. The prevalence increases in patients which do not respond to the gluten-free diet or with a concomitant lactose intolerance²⁴.

SIBO was found in about 25% of patients affected by Crohn's disease, especially in patients undergoing surgery²⁵.

Besides a lower absorption capacity, the short bowel syndrome brings to an accelerate transit of chimes, and consequently to a failure of food digestion. In particular the loss of the oro-cecal valve allow the passage of bacterial flora from the colon to the small bowel.

SIBO is also associated with liver disease. The gut alteration and the slow transit²⁶ due to portal hypertension in liver cirrhosis predispose to development of SIBO²⁷, which is itself a risk factor for the onset of spontaneous bacterial peritonitis²⁸, the pathogenesis being still not fully clarified.

Clinical patterns

Small intestinal bacterial overgrowth is generally considered a malabsorption syndrome, although the clinical manifestations largely vary in different subjects. Many factors such as the entity of contamination, the intestinal tract affected, the underlying predisposing conditions and the bacterial species involved may help to explain this strong variability². In particular, disorders associated to failure of intestinal clearance (due to failure of small bowel motility or intestinal anatomical abnormalities) generally lead to a more symptomatic and severe SIBO. In fact, in the presence of failure of intestinal clearance, SIBO is often distal, colonizing ileum and jejunum, only occasionally arriving to duodenum and stomach. Prevalent bacteria are enterobacteriaceae (in severe forms strict anaerobic species of colonic type could be observed). In the presence of failure of the gastric acid barrier, SIBO is often proximal (stomach, duodenum, proximal jejunum) and prevalent bacteria are Gram positive bacteria coming from upper respiratory tract²⁹.

SIBO may be asymptomatic or have symptoms such as fullness, abdominal pain, flatulence, diarrhoea, dyspepsia, malabsorption of nutrients, weight loss or no weight gain³⁰ and/or signs of malabsorption, similar to those observed in IBS patients³¹. The presence of a high bacterial load in the small intestine causes a precocious and abnormal deconjugation of bile acids with increased resorption at jejunal and secondary malabsorption of lipids³².

In severe cases there are signs of malabsorption (weight loss, steatorrhoea, malnutrition), liver lesion, a skin manifestation (rosacea), arthralgias and deficiency syndromes (anaemia, tetany in hypoglycaemia induced by vitamin D deficiency, metabolic bone disease, polyneuropathy due to vitamin B12 deficiency, etc.)³³.

In the latter spectrum of pathophysiological events the most important aspect is the malabsorption carbohydrates; the presence of bacteria in fact determines a marked luminal fermentation of these molecules, with overproduction of water, short chain fatty acids and gases (including carbon dioxide, hydrogen and methane)³⁴.

In most cases, however, the SIBO presents with a nonspecific intestinal symptoms such as watery diarrhoea (no evidence of steatorrhoea), pain, abdominal distension and flatulence, similar to those observed in patients affected by irritable bowel syndrome (IBS)³⁵⁻³⁷.

It has been suggested a possible pathogenic correlation between SIBO and IBS and a possible role of SIBO in determining the symptoms of IBS. It is known that about 92% of IBS patients have symptoms mainly characterized by bloating and pain. Although the majority of patients laments the onset of such symptoms after the intake of food, however, is often impossible to identify a specific food trigger. Bloating is associated with an increase in gas primarily in the small intestine. In physiological conditions, the production of hydrogen and other gases by bacteria occurs in the distal intestinal tract, since the small intestine hosts a bacterial flora that do not exceed 10^5 organisms per ml. In patients with SIBO the fermentation of substrates was achieved already at the level of the small intestine, resulting in the onset of intestinal symptoms quite comparable to that of patients with IBS.

SIBO may play a role in IBS: in particular, some trials reported a high prevalence of SIBO in IBS (78-84%) and a significant improvement in IBS symptoms after eradication³⁸⁻⁴⁰.

Lupascu et al has used the glucose breath test to evaluate the presence of SIBO, comparing a group of patients who met the Rome II criteria

for IBS and a group of healthy controls and finding a positive test in 30.7% of patients with IBS compared with 3.9% of controls ($p < 0.05$)³⁷.

The correlation between SIBO and IBS seems to find its explanation in the pathophysiology of alterations motility of the small intestine and in the activation of inflammation at the level of the intestinal wall.

SIBO diagnosis

The gold standard for diagnosis of SIBO is still aspiration and direct culture of the jejunal aspirate⁴¹. The principal limitation of this test are: high costs, invasivity, scarce reproducibility, bacteria cultivation-resistance, possible contaminations by oropharyngeal flora². In addition, the irregular distribution of bacteria may lead to false negatives².

For these reasons hydrogen breath tests (H²BT) are the most common diagnostic tool for SIBO, diagnosis since they are noninvasive, cheap, simple and safe. These tests are based on the measurement of hydrogen (and methane) in breath samples: these gases are produced by bacteria as a consequence of carbohydrate fermentation⁴² after oral ingestion of glucose and lactulose, pass through the blood circulation and reach the lung, where are expelled. So the diagnosis of SIBO is established on the increase of hydrogen value respect the baseline sample.

Unfortunately, breath tests have not yet been standardized, in term of substrate concentration, duration of tests, time intervals of breath sampling and cut-off values. The Consensus Rome Conference established that after the baseline breath sample there should be administrated 50 g of glucose and 10 g of lactulose: measurement then occurs every 15 minutes for 2 or 4 hours, respectively for the glucose and lactulose breath test⁴¹.

Glucose is rapidly absorbed in the proximal small bowel and usually does not reach the colon, so it is a suitable substrate to detect proximal small bowel overgrowth. A rise in H², after the assumption of the substrate, means that glucose meets bacteria in the small bowel, before its absorption. Because of its early absorption, GBT may not able to diagnose SIBO of the distal small intestine (ileum). According to most authors, the diagnosis of SIBO is established when the hydrogen level measured in breath sample increases ≥ 12 parts per million at 120 min respect the baseline value for glucose breath test (GBT). Sensitivity and specificity are 62.5% and 77.8 %, respectively compared to the gold standard (jejunal culture)⁴¹.

A variety of criteria have been used for defining a positivity for the lactulose breath test¹⁶: pick of hydrogen > 20 ppm above baseline in 90 or 180 min^{43,44}, methane increase > 5³⁹ or > 10 ppm⁴⁵ above baseline, dual hydrogen peaks 10 ppm above baseline with a decrease of 5 ppm from before the second peak³⁹, and two consecutive hydrogen peaks of 10 ppm above baseline that is different from the colonic peak defined as being 20 ppm above baseline. At present, the most used criterion is the presence of two peaks, the first due to bacterial activity in the small intestine (SIBO) and the second when lactulose reaches the colon. However, it is difficult to differ between an early H₂ peak caused by SIBO and a fast transit; thus, the non-standardized criteria, and lower diagnostic accuracy (55% versus 71% of Glucose)⁴¹ makes lactulose breath test not indicated to diagnostic for SIBO.

Some authors suggested that methane measurement on breath samples may increase diagnostic accuracy of sugars breath test by the identification of the so called “methane-producers” subgroup of SIBO patients. However, available data led Rome Consensus Conference to not recommend at present to assess methane in glucose breath testing to improve its sensitivity⁴¹.

An alternative breath test for the diagnosis of SIBO is represented by the choly¹⁻¹³C-glycine hydrolase breath test. It is based on the deconjugation of choly¹⁻¹³C-glycine fact that will be more rapid in bacterial overgrowth⁶. The reported sensitivity for this test is 70%: the false negative can be attributed to the possible lack of choly-glycine hydrolase in colonization bacteria, while on the other hand, bile acids could bring to a rapid deconjugation of cholyglycine in the proximal colon⁴⁶ and, consequently, to a false positive result. Lactose ¹³C-ureide breath test has been proposed as a diagnostic tool for SIBO diagnosis: its specificity is 100%, with a lower reported sensitivity (66%) when compared to the gold standard culture on intestinal aspirate⁴⁷. At present, these two tests utilizing ¹³C are not clearly superior in terms of accuracy with respect to hydrogen glucose breath test, in the face of higher costs and the necessity of a mass spectrometer for the measurements.

SIBO recurrence is a common event in the case of persistence of predisposing conditions, being often chronic and difficult or impossible to definitively removed. Recurrence was observed in about 40% of successfully treated SIBO subjects that had IBS as predisposing condition at 9 months-follow up⁸. Interestingly a good correlation was observed among SIBO recurrence, gas-

trointestinal symptoms relapse and GBT abnormal results, thus, suggesting that GBT is an useful diagnostic tool to monitor SIBO patients after antibiotic decontamination⁸. Similar percentage of recurrence were recently observed in patients with Parkinson’s disease and SIBO positivity at 6 months since eradication⁴⁸.

Conclusions

SIBO is often underdiagnosed in the clinical practice. It should be suspected in the presence of predisposing disorders, that are clinical conditions associated to an impairment of one or more of the physiologic mechanisms of the human host to prevent abnormal growth of gut flora.

According to literature data, Rome Consensus Conference suggests to use the hydrogen breath test (especially glucose breath test) to achieve SIBO diagnosis.

SIBO is often a recurrent disorder also after successful antibiotic decontamination, when the associated predisposing condition/s is/are not removable. For this reason it is important to clinically monitor the patients in the time, and, in the presence of symptoms relapse, the physician should consider SIBO recurrence, then administering to the patient hydrogen breath test to confirm SIBO diagnosis.

Conflict of interest

The Authors declare that they have no conflict of interests.

References

- 1) LUCKEY TD. Introduction to intestinal microecology. *Am J Clin Nutr* 1972; 25: 1292-1294.
- 2) GASBARRINI A, LAURITANO EC, GABRIELLI M, SCARPELLINI E, LUPASCU A, OJETTI V, GASBARRINI G. Small intestinal bacterial overgrowth: diagnosis and treatment. *Dig Dis* 2007; 25: 237-240.
- 3) HOOPER LV, MIDTVEDT T, GORDON JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. *Annu Rev Nutr* 2002; 22: 283-307.
- 4) HAO WL, LEE YK. Microflora of the gastrointestinal tract: a review. *Methods Mol Biol* 2004; 268: 491-502.
- 5) RIORDAN SM, MCLIVER CJ, WAKEFIELD D, DUNCOMBE VM, THOMAS MC, BOLIN TD. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. *Am J Gastroenterol* 2001; 96: 494-500.

- 6) BURES J, CYRANY J, KOHOUTOVA D, FÖRSTL M, REJCHRT S, KVETINA J, VORISEK V, KOPACOVA M. Small intestinal bacterial overgrowth syndrome. *World J Gastroenterol* 2010; 16: 2978-2990.
- 7) VESA TH, MARTEAU P, KORPELA R. Lactose intolerance. *J Am Coll Nutr* 2000; 19(2 Suppl): 165S-175S.
- 8) LAURITANO EC, GABRIELLI M, SCARPELLINI E, LUPASCU A, NOVI M, SOTTILI S, VITALE G, CESARIO V, SERRICCHIO M, CAMMAROTA G, GASBARRINI G, GASBARRINI A. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. *Am J Gastroenterol* 2008; 103: 2031-2035.
- 9) ELPHICK DA, CHEW TS, HIGHAM SE, BIRD N, AHMAD A, SANDERS DS. Small bowel bacterial overgrowth in symptomatic older people: can it be diagnosed earlier? *Gerontology* 2005; 51: 396-401.
- 10) LEWIS SJ, FRANCO S, YOUNG G, O'KEEFE SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. *Aliment Pharmacol Ther* 1996; 10: 557-561.
- 11) TRESPI E, FERRIERI A. Intestinal bacterial overgrowth during chronic pancreatitis. *Curr Med Res Opin* 1999; 15: 47-52.
- 12) FRIDGE JL, CONRAD C, GERSON L, CASTILLO RO, COX K. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. *J Pediatr Gastroenterol Nutr* 2007; 44: 212-218.
- 13) BELITSOS PC, GREENSON JK, YARDLEY JH, SISLER JR, BARTLETT JG. Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS. *J Infect Dis* 1992; 166: 277-284.
- 14) PIGNATA C, BUDILLON G, MONACO G, NANI E, CUOMO R, PARRILLI G, CICCIMARRA F. Jejunal bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes. *Gut* 1990; 31: 879-882.
- 15) LOMBARDO L, FOTI M, RUGGIA O, CHIECCHIO A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. *Clin Gastroenterol Hepatol* 2010; 8: 504-508.
- 16) GEORGE NS, SANKINENI A, PARKMAN HP. Small Intestinal Bacterial Overgrowth in Gastroparesis. *Dig Dis Sci* 2012. [Epub ahead of print].
- 17) GOTO S, BILLMIRE DF, GROSFELD JL. Hypothyroidism impairs colonic motility and function. An experimental study in the rat. *Eur J Pediatr Surg* 1992; 2: 16-21.
- 18) SHAFER RB, PRENTISS RA, BOND JH. Gastrointestinal transit in thyroid disease. *Gastroenterology* 1984; 86(5 Pt 1): 852-855.
- 19) TURSİ A, BRANDIMARTE G, GIORGETTI GM, ELISEI W. Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. *World J Gastroenterol* 2005; 11: 2773-2776.
- 20) RUBIO-TAPIA A, BARTON SH, ROSENBLATT JE, MURRAY JA. Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease. *J Clin Gastroenterol* 2009; 43: 157-161.
- 21) GHOSHAL UC, GHOSHAL U, MISRA A, CHOUDHURI G. Partially responsive celiac disease resulting from small intestinal bacterial overgrowth and lactose intolerance. *BMC Gastroenterol* 2004; 4: 10.
- 22) TURSİ A, BRANDIMARTE G, GIORGETTI G. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. *Am J Gastroenterol* 2003; 98: 839-843.
- 23) KRAUSS N, SCHUPPAN D. Monitoring nonresponsive patients who have celiac disease. *Gastrointest Endosc Clin N Am* 2006; 16: 317-327.
- 24) CASTIGLIONE F, RISPO A, DI GIROLAMO E, COZZOLINO A, MANGUSO F, GRASSIA R, MAZZACCA G. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. *Aliment Pharmacol Ther* 2003; 18: 1107-1112.
- 25) CHANG CS, CHEN GH, LIEN HC, YEH HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. *Hepatology* 1998; 28: 1187-1190.
- 26) Bauer TM, Steinbrückner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, Pelz K, Kist M, Blum HE. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. *Am J Gastroenterol* 2001; 96: 2962-2967.
- 27) LATA J, STIBUREK O, KOPACOVA M. Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis. *World J Gastroenterol* 2009; 15: 5505-5510.
- 28) HUSEBYE E. The pathogenesis of gastrointestinal bacterial overgrowth. *Chemotherapy* 2005; 51(Suppl 1): 1-22.
- 29) KING T. Small intestinal bacterial overgrowth and irritable bowel syndrome. *JAMA* 2004; 292: 2213; author reply 2213-2214.
- 30) DONALDSON RM JR. Normal bacterial populations of the intestine and their relation to intestinal function. *N Engl J Med* 1964; 270: 1050-1056.
- 31) WANITSCHKE R, AMMON HV. Effects of dihydroxy bile acids and hydroxy fatty acids on the absorption of oleic acid in the human jejunum. *J Clin Invest* 1978; 61: 178-186.
- 32) SALTZMAN JR, RUSSELL RM. Nutritional consequences of intestinal bacterial overgrowth. *Compr Ther* 1994; 20: 523-530.
- 33) NUCERA G, GABRIELLI M, LUPASCU A, LAURITANO EC, SANTOLLIQUIDO A, CREMONINI F, CAMMAROTA G, TONDI P, POLA P, GASBARRINI G, GASBARRINI A. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. *Aliment Pharmacol Ther* 2005; 21: 1391-1395.
- 34) LIN HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. *JAMA* 2004; 292: 852-858.
- 35) SALTZMAN JR, KOWDLEY KV, PEDROSA MC, SEPE T, GOLNER B, PERRONE G, RUSSELL RM. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. *Gastroenterology* 1994; 106: 615-623.
- 36) LUPASCU A, GABRIELLI M, LAURITANO EC, SCARPELLINI E, SANTOLLIQUIDO A, CAMMAROTA G, FLORE R, TONDI P, POLA P, GASBARRINI G, GASBARRINI A. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. *Aliment Pharmacol Ther* 2005; 22: 1157-1160.

- 38) SINGH VV, TOSKES PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. *Curr Treat Options Gastroenterol* 2004; 7: 19-28.
- 39) PIMENTEL M, CHOW EJ, LIN HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. *Am J Gastroenterol* 2000; 95: 3503-3506.
- 40) PIMENTEL M, CHOW EJ, LIN HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol* 2003; 98: 412-419.
- 41) GASBARRINI A, CORAZZA GR, GASBARRINI G, MONTALTO M, DI STEFANO M, BASILISCO G, PARODI A, USAI-SATTA P, VERNIA P, ANANIA C, ASTEGIANO M, BARBARA G, BENINI L, BONAZZI P, CAPURSO G, CERTO M, COLECCHIA A, CUOCO L, DI SARIO A, FESTI D, LAURITANO C, MICELI E, NARDONE G, PERRI F, PORTINCASA P, RISICATO R, SORGE M, TURSÌ A; 1st Rome H2-Breath Testing Consensus Conference Working Group. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. *Aliment Pharmacol Ther* 2009; 29(Suppl 1): 1-49.
- 42) ROMAGNUOLO J, SCHILLER D, BAILEY RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. *Am J Gastroenterol* 2002; 97: 1113-26.
- 43) RHODES JM, JEWELL DP. Lactulose hydrogen breath test in the diagnosis of bacterial overgrowth. *Gastroenterology* 1990; 99: 1547.
- 44) YU D, CHEESEMAN F, VANNER S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. *Gut* 2011; 60: 334-40.
- 45) REDDYMASU SC, MCCALLUM RW. Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? *J Clin Gastroenterol* 2010; 44: e8-13.
- 46) FROMM H, THOMAS PJ, HOFMANN AF. Sensitivity and specificity in tests of distal ileal function: prospective comparison of bile acid and vitamin B 12 absorption in ileal resection patients. *Gastroenterology* 1973; 64: 1077-1090.
- 47) BERTHOLD HK, SCHOBEL P, SCHEURLIN C, MARKLEIN G, HORRÉ R, GOUNI-BERTHOLD I, SAUERBRUCH T. Use of the lactose-[13C]ureide breath test for diagnosis of small bowel bacterial overgrowth: comparison to the glucose hydrogen breath test. *J Gastroenterol* 2009; 44: 944-951.
- 48) GABRIELLI M, BONAZZI P, SCARPELLINI E, BENDIA E, LAURITANO EC, FASANO A, CERAVOLO MG, CAPECCI M, RITA BENTIVOGLIO A, PROVINCIALI L, TONALI PA, GASBARRINI A. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. *Mov Disord* 2011; 26: 889-892.